GlassScriptPhysician profile
Elizabeth Fuller
NPI 1679964720
$4,729.31
in general payments reported to CMS, 2019-2025
35 companies · $983 in 2025
The $983 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $756 · 2022: $868 · 2023: $878 · 2024: $1,243 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,108.19 | 2021-2025 | |
| Novo Nordisk INC | $828.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $777.64 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $396.90 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $360.26 | 2022-2025 | |
| Abbott Laboratories | $219.53 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $147.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.19 | 2022-2025 | Jardiance |
| Eisai INC. | $76.72 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.59 | 2021-2023 | Xifaxan |
| Hologic Sales and Service, LLC | $55.28 | 2021-2022 | |
| Astellas Pharma US INC | $52.35 | 2021-2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $47.19 | 2022-2025 | Recorlev |
| Sumitomo Pharma America, INC. | $42.90 | 2023 | Gemtesa |
| Amgen INC. | $38.44 | 2024-2025 | Krystexxa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $33.19 | 2023-2024 | Accrufer |
| Glaxosmithkline, LLC. | $31.73 | 2023-2024 | Shingrix, Arexvy |
| Medtronic, INC. | $25.11 | 2021-2023 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $24.13 | 2021 | |
| Biogen, INC. | $23.52 | 2025 | Leqembi |
| Ardelyx, INC. | $23.42 | 2024 | Ibsrela |
| Emmaus Medical, INC. | $22.41 | 2021 | |
| Boston Scientific Corporation | $21.72 | 2025 | Resolution 360 Ultra Clip |
| Evoke Pharma, INC. | $21.13 | 2022 | |
| Ibsa Pharma INC. | $19.56 | 2025 | Flector, Licart, Tirosint |
| Sanofi-Aventis U.S. LLC | $18.84 | 2022 | |
| Tris Pharma INC | $17.14 | 2024 | Dyanavel Xr |
| Lundbeck LLC | $16.16 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $15.28 | 2021 | |
| Lilly USA, LLC | $15.15 | 2025 | Kisunla |
| Currax Pharmaceuticals LLC | $14.97 | 2022 | |
| Dynavax Technologies Corporation | $14.81 | 2023 | Heplisav-B |
| Alk-Abello, INC | $14.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.25 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.